

References: Spotlight on drugs Advanced course 2019

Dr Andrew Wilcock

Pancreatin

- Dominguez-Munoz JE (2018) Diagnosis and treatment of pancreatic exocrine insufficiency. *Current Opinion Gastroenterology Journal*. **34**: 349–354.
- Dominguez-Munoz JE and Iglesias-Garcia J (2010) Oral pancreatic enzyme substitution therapy in chronic pancreatitis: Is clinical response an appropriate marker for evaluation of therapeutic efficacy? *Journal of the Pancreas*. **11**: 158–162.
- Imrie CW *et al.* (2010) Review article: Enzyme supplementation in cystic fibrosis, chronic pancreatitis, pancreatic and periampullary cancer. *Alimentary Pharmacology & Therapeutics*. **32** (Suppl 1): 1–25.
- UKMI (2018) What factors to consider when advising on medicines suitable for a halal diet. *Medicines Q&As*. www.sps.nhs.uk
- Pancreatic Cancer Action My religion restricts me from eating pork, so can I still take pancreatic enzymes? *Pancreatic enzyme replacement therapy (PERT)* www.pancreaticcanceraction.org (Accessed February 2019).
- NICE (2018) Pancreatic cancer in adults: Diagnosis and management. *Clinical Guidelines* (NG85). www.nice.org.uk
- Dominguez-Munoz JE *et al.* (2018a) Impact of the treatment of pancreatic exocrine insufficiency on survival of patients with unresectable pancreatic cancer: A retrospective analysis. *BMC Cancer*. **18**: 534.
- Löhr JM *et al.* (2017) United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis. *United European Gastroenterology Journal*. **5**: 153–199.
- Hausler M *et al.* (1998) First adult patient with fibrosing colonopathy. *American Journal of Gastroenterology*. **93**: 1171–1172.
- Bansi DS *et al.* (2000) Fibrosing colonopathy in an adult owing to over use of pancreatic enzyme supplements. *Gut*. **46**: 283–285.
- Bruno MJ *et al.* (1998) Placebo controlled trial of enteric coated pancreatin microsphere treatment in patients with unresectable cancer of the pancreatic head region. *Gut*. **42**: 92–96.

Ketamine

- Bell RF *et al.* (2017) Ketamine as an adjuvant to opioids for cancer pain. *Cochrane Database of Systematic Reviews*. 6: CD003351.
- Yang CY *et al.* (1996) Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. *Canadian Journal of Anaesthesia*. **43**:379–383.
- Mercadante S *et al.* (2000) Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study. *Journal of Pain and Symptom Management*. **20**:246–252.

- Hardy J *et al.* (2012) Randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. *Journal of Clinical Oncology*. **30**:11–17.
- Fallon MT *et al.* (2018) Oral ketamine vs placebo in patients with cancer-related neuropathic pain: A randomized controlled clinical trial. *JAMA Oncology*. **4**:870-872.
- Bosma RL *et al.* (2018) Brain dynamics and temporal summation of pain predicts neuropathic pain relief from ketamine infusion. *Anesthesiology*. **129**:1015-1024.
- Bell RF and Kalso EA (2018) Ketamine for pain management. *Pain reports*. **3**: e674.
- Liu SYW *et al.* (2017) Clinical pattern and prevalence of upper gastrointestinal toxicity in patients abusing ketamine. *Journal of Digestive Disorders*. **18**:504-510.

Developments in opioid analgesics

Overview

Cunningham CW *et al.* (2019) Bifunctional opioid receptor ligands as novel analgesics. *Neuropharmacology*. Epub ahead of print.

- Gunther T *et al.* (2018) Targeting multiple opioid receptors – improved analgesics with reduced side effects. *British Journal of Pharmacology*. **175**:2857-2868.
- Chan HCS *et al.* (2017) Designing safer analgesics via μ -opioid receptor pathways. *Trends in Pharmacology Science*. **38**:1016-1037.
- Scholz A *et al.* (2018) Cebranopadol: A novel, first-in-class, strong analgesic: Results from a randomized phase IIa clinical trial in postoperative acute pain. *Pain Physician*. **21**:E193-E205.
- Christoph A *et al.* (2017) Cebranopadol, a novel first-in-class analgesic drug candidate: first experience in patients with chronic low back pain in a randomized clinical trial. *Pain*. **158**:1813-1824.
- Dahan A *et al.* (2017) Respiratory effects of the Nociception/Orphanin FQ peptide and opioid receptor agonist, cebranopadol, in healthy human volunteers. *Anesthesiology*. **126**:697-707.
- Eerdekens M-H *et al.* (2019) Cancer-related chronic pain: investigation of the novel analgesic drug candidate cebranopadol in a randomized, double-blind, noninferiority trial. *European Journal of Pain*. **23**: 577-588.
- Gohler K *et al.* (2019) Assessment of the abuse potential of cebranopadol in nondependent recreational opioid users. A phase 1 randomized controlled study. *Journal of Clinical Psychopharmacology*. **39**:46-56.
- Ding H *et al.* (2016) A novel orvinol analog, BU08028, is a safe opioid analgesic without abuse liability in primates. *Proc Natl Acad Sci USA*. **113**:E5511-8.
- Rodriguez-Gaztelumendi A *et al.* (2018) Analgesic effects of a novel pH-dependent μ -opioid receptor agonist in models of neuropathic and abdominal pain. *Pain*. [Epub ahead of print]
- Spahn V *et al.* (2017) A nontoxic pain killer designed by modeling of pathological receptor conformations. *Science*. **355**:966-969.
- Urtis I *et al.* (2019) The utilization of μ -opioid receptor biased agonists: oliceridine, an opioid analgesic with reduced adverse effects. *Current Pain and Headache Reports*. **23**:31.

- Singla N *et al.* (2017) A randomized, Phase IIb study investigating oliceridine (TRV130), a novel μ -receptor G-protein pathway selective (μ -GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty. *Journal of Pain Research*. **10**:2413-2424.
- Viscusi ER *et al.* (2019) APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the mu-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy. *Journal of Pain Research*. **12**: 927-943.
- Viscusi ER *et al.* (2016) A randomized, phase 2 study investigating TRV130, a biased ligand of the μ -opioid receptor, for the intravenous treatment of acute pain. *Pain*. **157**:264-272.
- Stevens Negus S *et al.* (2018) Abuse potential of biased mu opioid receptor agonists. *Trends in Pharmaceutical Sciences*. **39**:916-919.
- Hill R *et al.* (2018) The novel μ -opioid receptor agonist PZM21 depresses respiration and induces tolerance to antinociception. *British Journal of Pharmacology*. **175**:2653-2661.